SERFELIZ SC

About SERFELIZ SC

Cyrille Tupin is a French biopharmaceutical executive best known for serving as Chief Executive Officer of ABIONYX Pharma, a role he has held since September 6, 2019. In that position, he leads the group’s overall strategy, operational execution, and corporate development, with a focus on ABIONYX’s bio-HDL assets and its programs in ophthalmology and nephrology. ABIONYX’s universal registration documents also show that his influence extends beyond management, as his control of the company Serfeliz places him among the group’s long-standing reference shareholders and key governance stakeholders. Under his leadership, ABIONYX Pharma has continued its evolution as a next-generation biotech company dedicated to innovative therapies for diseases with no effective existing treatment. The group emphasizes development programs in renal disease, ophthalmological disease, and HDL-based vectors designed for targeted drug delivery. This strategic direction requires close oversight of scientific partnerships, financial resources, regulatory milestones, and intellectual property. Public disclosures indicate that the company has strengthened its asset base, group structure, and clinical and preclinical development efforts in a highly demanding environment. Tupin’s role is also rooted in the governance of a listed company, with responsibilities linked to board-level decisions, growth planning, and the internal arrangements needed to support continuity of leadership. ABIONYX’s public filings reference specific contractual arrangements associated with his mandate, underscoring a framework designed to secure managerial stability and align executive and corporate interests. His profile therefore reflects that of an experienced biotech leader combining strategic oversight, market discipline, and a long-term commitment to value creation within a listed company context.